Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

Exclusion Criteria

• •No prior treatment with the following in the study eye:
• •* Subfoveal thermal laser therapy;
• •* Submacular surgery or other surgical intervention for the treatment of AMD;
• •* Extrafoveal laser coagulation treatment within 12 weeks prior to Day 1 (Visit 2);
• •* PDT or ITV administration of triamcinolone acetonide or any other steroid within 12 weeks prior to Day 1 (Visit 2);
• •* Pegaptanib sodium within 8 weeks of Day 1 (Visit 2);
• •* Juxtascleral steroids or anecortave acetate within 180 Days (6 months) prior to Day 1 (visit 2);
• •* Prior systemic or intravitreal treatment with VEGF Trap or bevacizumab;
• •* Any investigational agent for the treatment of eye disease within 12 weeks of Day 1 (Visit 2)
• •History of any vitreous hemorrhage within 4 weeks prior to baseline injection visit.
• •Aphakia or pseudophakia with the absence of a posterior capsule (unless it occurred as a result of a yttrium aluminum garnet \[YAG\] capsulotomy).
• •Significant subfoveal atrophy or scarring.
• •Any condition or laboratory abnormality that, in the opinion of the Investigator, would interfere with the assessment of disease status/progression or jeopardize the subject's appropriate participation in this study